MK-1045

Phase 1Biologic

Merck & Co.

MK-1045 is one of 214 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

213

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusRecruiting

LymphomaActive, not recruiting

Precursor B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Acute Lymphoblastic LeukemiaRecruiting

Rheumatoid ArthritisActive, not recruiting

Lymphoma, Non-HodgkinRecruiting

Refractory B-Cell Non-Hodgkin LymphomaRecruiting

B-Cell Acute Lymphoblastic LeukemiaRecruiting

Follicular LymphomaRecruiting

Systemic Lupus ErythematosusPhase 1

Recruiting

LymphomaPhase 1

Active, not recruiting

Precursor B-Cell Acute Lymphoblastic LeukemiaPhase 1/Phase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPreclinical

Recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Lymphoma, Non-HodgkinPreclinical

Recruiting

Refractory B-Cell Non-Hodgkin LymphomaPhase 1

Recruiting

B-Cell Acute Lymphoblastic LeukemiaPreclinical

Recruiting

Follicular LymphomaPreclinical

Recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Oncaspar

SServier

Preclinical

15 3

MK-1045

Merck & Co.

Phase 1

6 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Nuvigil

NNuvo Research GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Acute Lymphoblastic Leukemia

NCT05579132

Q1 2029

Phase 1Recruiting

Refractory B-Cell Non-Hodgkin Lymphoma

NCT06189391

Q3 2029

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT07363590

Q2 2031

PreclinicalRecruiting

Lymphoma, Non-Hodgkin

NCT07519772

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

An Open-label, Multi-center Phase Ib/II Study of MK-1045 (CN201) in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia

Recruiting·MMSD R&D (China) Co., Ltd.·Preclinical·NCT05579132·203 enrolled

Follicular Lymphoma1 trial

A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07634471·960 enrolled

B-cell acute lymphoblastic leukemia1 trial

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07570173·340 enrolled

Lymphoma, Non-Hodgkin1 trial

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07519772·200 enrolled

Refractory B-Cell Non-Hodgkin Lymphoma1 trial

An Open-Label, Dose Escalation Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-1045 (CN201) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting·MMSD R&D (China) Co., Ltd.·Phase 1·NCT06189391·100 enrolled

1 more indication

Systemic Lupus Erythematosus1 trial

A Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1045 in Participants With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07363590·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for MK-1045. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK-1045 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK-1045. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Merck & Co.

MK-1045

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Q3 2029

Q2 2031

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

Follicular Lymphoma1 trial

B-cell acute lymphoblastic leukemia1 trial

Lymphoma, Non-Hodgkin1 trial

Refractory B-Cell Non-Hodgkin Lymphoma1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News